Safety, Tolerance, PK, and Anti-tumour Activity of AZD1775 Monotherapy in Patients With Advanced Solid Tumours
|ClinicalTrials.gov Identifier: NCT02482311|
Recruitment Status : Active, not recruiting
First Posted : June 26, 2015
Last Update Posted : December 7, 2017
|Condition or disease||Intervention/treatment||Phase|
|Ovarian Cancer, TNBC, SCLC, Other Solid Tumours||Drug: AZD 1775||Phase 1|
This study is being conducted in two parts, designated Parts A and B. Part A is a safety lead-in consisting of a cohort of approximately 12 patients with advanced solid tumours.
Part B expansion cohorts will investigate AZD1775 monotherapy in advanced tumour types with molecular biomarkers of interest. The tumour types to be evaluated are: 1) ovarian cancer (BRCA1/2 mutation [PARP-failures]), 2) ovarian cancer (BRCA wild-type) with more than three prior lines of treatment, 3) triple negative breast cancer (TNBC), and 4) small-cell lung cancer (SCLC).
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||97 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Phase Ib, Open-Label, Multi-Centre Study to Assess the Safety, Tolerability, Pharmacokinetics, and Anti-tumour Activity of AZD1775 Monotherapy in Patients With Advanced Solid Tumours|
|Actual Study Start Date :||July 1, 2015|
|Estimated Primary Completion Date :||December 11, 2017|
|Estimated Study Completion Date :||December 11, 2017|
Single-arm study. AZD1775 will be administered for 3 consecutive days at the start of week 1 and week 2 of each 21-day cycle.
This study will be conducted in two parts, designated Part A and Part B. Part A is a safety lead-in. Part B will commence after the safety lead-in and will investigate the safety and efficacy of AZD1775 monotherapy in expansion cohorts of specific tumour types.
Drug: AZD 1775
AZD1775 will be taken orally approximately every 12 hours over 3 days at the start of week 1 and week 2 of each 21-day cycle (Days 1-3 and 8-10), for a total of 12 doses with each treatment cycle.
AZD1775 should be taken approximately 2 hours before or 2 hours after food.
- Number of treatment emergent adverse events (TEAEs), serious adverse events (SAEs) and dose-limiting toxicities (DLTs) as a measure of safety and tolerability. [ Time Frame: From first dose of study treatment up to last day of Cycle 1 (21 days) ]The AZD1775 dose is considered safe and tolerable if ≤ 1 of 6 patients experiences a DLT.
- Objective Response Rate (ORR) [ Time Frame: Every 6 weeks until treatment discontinuation as defined by RECIST 1.1, projected 12 months. ]The proportion of patients achieving a complete or partial tumour response (CR or PR) according to RECIST 1.1 criteria.
- Disease Control Rate (DCR) [ Time Frame: Every 6 weeks until treatment discontinuation as defined by RECIST 1.1, projected 12 months ]The proportion of patients achieving a complete response (CR) or partial response (PR), or stable disease (SD) according to RECIST v1.1 criteria
- Duration of Response (DoR) [ Time Frame: Every 6 weeks until treatment discontinuation as defined by RECIST 1.1, projected 12 months ]The time from first documented tumor response until the date of documented progression or death from any cause.
- Progression Free Survival (PFS) [ Time Frame: Every 6 weeks until treatment discontinuation as defined by RECIST 1.1, project 12 months. ]Defined as the time from date of first dose of AZD1775 until the date of objective disease progression or death by any cause as defined by RECIST 1.1.
- PK profile: Plasma concentrations of AZD1775 and PK parameters (Cmax, C8hr, tmax, AUC, tlast, t½λz) [ Time Frame: Pre-dose and 1, 2, 4, 6, 8 and 12 hours post-dose of AZD1775 during Cycle 1-Day 1 and Cycle 1-Day3 or Day-10 of the safety lead-in part of study ]Blood samples will be collected at various timepoints post-dosing
- QTc prolongation [ Time Frame: ECGs collected pre-dose and 1, 2, 4, 6, 8 and 12 hours post-dose in Cycle 1-Day 1 and on Cycle 1-Day 3 or Day 10. ]ECGs will be obtained at various timepoints
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02482311
|United States, Arkansas|
|Fayetteville, Arkansas, United States, 72703|
|United States, California|
|La Jolla, California, United States, 92093|
|Los Angeles, California, United States, 90048|
|San Francisco, California, United States, 94115|
|United States, Florida|
|Fort Myers, Florida, United States, 33905|
|United States, Indiana|
|Indianapolis, Indiana, United States, 46202|
|United States, Michigan|
|Detroit, Michigan, United States, 48201|
|United States, North Carolina|
|Charlotte, North Carolina, United States, 28204|
|United States, Oklahoma|
|Oklahoma City, Oklahoma, United States, 73104|
|United States, Pennsylvania|
|Philadelphia, Pennsylvania, United States, 19104|
|United States, South Carolina|
|Greenville, South Carolina, United States, 29605|
|United States, Tennessee|
|Nashville, Tennessee, United States, 37203|
|United States, Texas|
|Houston, Texas, United States, 77030|
|United States, Wisconsin|
|Milwaukee, Wisconsin, United States, 53226|
|Edmonton, Alberta, Canada, T6G 1Z2|
|Canada, British Columbia|
|Vancouver, British Columbia, Canada, V5Z 4E6|
|Toronto, Ontario, Canada, M5G 2M9|
|Principal Investigator:||Todd M. Bauer, MD||SCRI Development Innovations, LLC|